Clinical Trial Update: Open-Label Extension Study of Setmelanotide [Phase 3]

View source ↗

Summary

Phase 3 open-label extension study for setmelanotide completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity Associated with Defects in Leptin-melanocortin Pathway

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | Status: COMPLETED